| Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients C Blimark, E Holmberg, UH Mellqvist, O Landgren, M Björkholm, ... haematologica 100 (1), 107, 2015 | 524 | 2015 |
| Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes SY Kristinsson, M Björkholm, M Hultcrantz, ÅR Derolf, O Landgren, ... Journal of Clinical Oncology 29 (21), 2897, 2011 | 325 | 2011 |
| Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms M Björkholm, ÅR Derolf, M Hultcrantz, SY Kristinsson, C Ekstrand, ... Journal of clinical oncology 29 (17), 2410, 2011 | 292 | 2011 |
| Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008 M Björkholm, L Ohm, S Eloranta, Å Derolf, M Hultcrantz, J Sjöberg, ... Journal of Clinical Oncology 29 (18), 2514, 2011 | 252 | 2011 |
| Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study M Hultcrantz, M Björkholm, PW Dickman, O Landgren, ÅR Derolf, ... Annals of internal medicine 168 (5), 317-325, 2018 | 243 | 2018 |
| Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study M Hultcrantz, SY Kristinsson, TML Andersson, O Landgren, S Eloranta, ... Journal of clinical oncology 30 (24), 2995, 2012 | 239 | 2012 |
| GPRC5D-targeted CAR T cells for myeloma S Mailankody, SM Devlin, J Landa, K Nath, C Diamonte, EJ Carstens, ... New England journal of medicine 387 (13), 1196-1206, 2022 | 195 | 2022 |
| Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, L Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 18 (12), 1685-1717, 2020 | 190 | 2020 |
| Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study M Hultcrantz, SR Wilkes, SY Kristinsson, TML Andersson, ÅR Derolf, ... Journal of Clinical Oncology 33 (20), 2288-2295, 2015 | 139 | 2015 |
| NCCN Guidelines® insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines NS Callander, M Baljevic, K Adekola, LD Anderson, E Campagnaro, ... Journal of the National Comprehensive Cancer Network 20 (1), 8-19, 2022 | 125 | 2022 |
| Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study S Thorsteinsdottir, PW Dickman, O Landgren, C Blimark, M Hultcrantz, ... Haematologica 103 (9), e412, 2018 | 119 | 2018 |
| Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health … O Landgren, BI Graubard, S Kumar, RA Kyle, JA Katzmann, K Murata, ... Blood cancer journal 7 (10), e618-e618, 2017 | 107 | 2017 |
| Revealing the impact of structural variants in multiple myeloma EH Rustad, VD Yellapantula, D Glodzik, KH Maclachlan, B Diamond, ... Blood cancer discovery 1 (3), 258-273, 2020 | 96 | 2020 |
| Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I … S Mailankody, A Ghosh, M Staehr, TJ Purdon, M Roshal, E Halton, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 87 | 2018 |
| Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities B Oben, G Froyen, KH Maclachlan, D Leongamornlert, F Abascal, ... Nature communications 12 (1), 1861, 2021 | 83 | 2021 |
| COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood cancer discovery 1 (3), 234-243, 2020 | 83 | 2020 |
| Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the … O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, ... JAMA oncology 7 (6), 862-868, 2021 | 79 | 2021 |
| Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients AR Landtblom, H Bower, TML Andersson, PW Dickman, J Samuelsson, ... Leukemia 32 (10), 2203-2210, 2018 | 78 | 2018 |
| Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma O Landgren, JN Hofmann, CM McShane, L Santo, M Hultcrantz, N Korde, ... JAMA oncology 5 (9), 1293-1301, 2019 | 73 | 2019 |
| Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... Blood Cancer Journal 11 (5), 94, 2021 | 70 | 2021 |
